Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), has recently been identified within the bone marrow dendritic cells of multiple myeloma (MM) patients. This virus contains homologues to human cytokines such as IL-6 that could potentially stimulate myeloma cell growth and contribute to disease pathogenesis. Since mobilization chemotherapy may increase circulating dendritic cell numbers, we searched for HHV-8 in peripheral blood mononuclear cells (PBMCs) before and after mobilization chemotherapy given to MM patients. Furthermore, we determined if autograft purging using the CEPRATE SC device would reduce the percentage of HHV-8 infected stem cell products. Only two of the 39 PBMC samples collected prior to mobilization chemotherapy contained PCR detectable virus, yet nine of 37 PBMCs collected on the first day of leukapheresis had detectable HHV-8 (P = 0.016). HHV-8 was more frequently identified in autograft products before vs after Ceprate SC selection (40% vs 15%, P = 0.016). Although the role HHV-8 plays in myeloma pathogenesis remains unclear, these results imply that mobilization chemotherapy increases the numbers of circulating HHV-8-infected dendritic cells within the peripheral blood. In addition, CD34 selection of autograft products in MM patients may reduce the reintroduction of virally infected cells following high-dose chemotherapy. Bone Marrow Transplantation (2000) 25, 153-160. Keywords: human herpesvirus 8; Kaposi's sarcomaassociated herpesvirus; multiple myeloma; pathogenesis; autologous transplantation; leukapheresis Multiple myeloma is a malignancy of terminally differentiated plasma cells that proliferate within the bone marrow resulting in bony destruction, anemia and immune dysfuncCorrespondence: RA Vescio,
tion. The disease is incurable with standard multi-agent chemotherapy, with most large studies reporting median survival times of less than 3 years. 1 In an attempt to improve these results, high-dose chemotherapy followed by autologous transplantation has been shown to improve disease-free and overall survival in a randomized phase III trial. 2 Nevertheless, the majority of patients transplanted with autologous hematopoietic support develop progressive disease within 3 years due to either the re-infusion of contaminating malignant cells within the autograft or, more likely, the inability of the high-dose therapy to eradicate the host myeloma tumor burden. [3] [4] [5] [6] [7] [8] Epidemiological evidence suggested that an infectious agent could be responsible for the development of Kaposi's sarcoma in AIDS patients. 9 Using representational difference analysis, a new gamma herpesvirus was identified within Kaposi's sarcoma tumor cells and named Kaposi's sarcoma-associated herpesvirus (KSHV). 10 The entire viral genome, now more commonly labeled human herpesvirus-8 (HHV-8), has been sequenced and found to contain numerous human cytokine homologues such as functional forms of interleukin-6 (IL-6), bcl-2 and macrophage inhibitory factors (MIP1␣, MIP1␤). 11, 12 Viral DNA was later identified within pleural effusion lymphomas, 13 and multicentric Castleman's disease, 14 (diseases related by the significant role IL-6 plays in their growth), but not in other hematologic malignancies.
We have subsequently identified HHV-8 DNA within the supporting non-malignant bone marrow stromal cells of patients with multiple myeloma. 15 These cultured cells were found to be dendritic in origin and to express transcripts of viral genes such as the homologue of IL-6 (vIL-6) and bcl-2 (vbcl-2). While HHV-8 DNA was rarely identified within the peripheral blood of these same patients, following immunomagnetic bead enrichment for cells bearing the dendritic cell markers CD68 and CD83, viral genome was frequently identified using the polymerase chain reaction with primers to viral ORF26. 16 Since the use of flt-3 ligand to mobilize stem cells was found to increase circulating dendritic cell numbers 30-fold, 17 we questioned whether the mobilization chemotherapy regimen used in our patients undergoing autologous peripheral blood stem cell transplantation may also mobilize HHV-8 infected dendritic cells. We also determined whether CD34 enrichment of leukapheresis products could reduce autograft viral load.
Materials and methods

Patient selection
All patient material came from persons diagnosed with multiple myeloma who were Ͻ70 years old and had evidence of an elevated ␤-2 microglobulin or Durie-Salmon stage II/III disease 18 as a marker of adverse prognosis. Patients had received 3-6 months of therapy without evidence of disease progression and were subsequently enrolled on a multi-institutional phase III trial comparing CD34 selected (Arm A) vs unselected (Arm B) peripheral blood stem cell (PBSC) autologous transplantation. All samples assessed in this paper were from patients on Arm A of this randomized trial.
Treatment protocol
Cyclophosphamide (2.5 g/m 2 day 1), prednisone (2 mg/kg/day, day 1-4) and G-CSF (10 g/kg/day, day 2-leukapheresis completion) were administered to each patient to mobilize stem cells for collection. Leukapheresis was initiated at day 15 (initial 59 patients) or when the WBC count increased to Ͼ1000 /l for 2 consecutive days (remaining 134 patients). Autologous PBSC were procured using standard procedures and processed using the Ceprate SC stem cell concentration system (Cellpro, Bothell, WA, USA). Aliquots from the initial leukapheresis, CD34-enriched and depleted products were obtained from each patient. Peripheral blood samples were collected prior to mobilization chemotherapy and on the first day of leukapheresis. All samples were shipped via overnight mail for processing within our laboratory.
HHV-8 identification
Mononuclear cells were obtained from the peripheral blood specimens following Histopaque 1077 (Sigma, St Louis, MO, USA) centrifugation. DNA was then extracted from peripheral blood mononuclear cells (PBMCs), leukapheresis, CD34-enriched (CD34 + ) and CD34-depleted (CD34 − ) products using the Easy-DNA kit (Invitrogen, La Jolla, CA, USA) and quantified using a fluorometer (Hoeffer Scientific, San Francisco, CA, USA). HHV-8 was identified by using the polymerase chain reaction (PCR) on 0.6 g of genomic DNA (ෂ100 000 cells worth of DNA) and primers specific for the KS330 233 sequence. 10 A second set of primers to HHV-8 ORFK9 were used on a subset of samples (5Ј TGTGGTGGCTGCGATAAC 3Ј) (5Ј TCTTCGTCTTCCCACTCTA 3Ј). Forty-five cycles of amplification were performed using Buffer 'B' of the PCR Optimizer kit (Invitrogen), Taq polymerase (Perkin Elmer, Norwalk, CT, USA) and Taq Antibody (Clontech, Palo Alto, CA, USA) following the manufacturer's recommendations. Each PCR cycle consisted of 1 min at 95°C, 90 s at 55°C, and 2 min at 72°C, following an initial denaturation step at 95 o C for 5 min. As a positive control, 0.6 g of DNA from the same specimen was PCR amplified using ␤-actin primers (Stratagene, La Jolla, CA, USA). Amplification of DNA from the KS-1 cell line 19 also served as a positive control for each PCR run. A PCR tube without DNA and one with 0.6 g of placental DNA were amplified at the same time and served as negative controls. PCR products were electrophoresed through an ethidium bromideimpregnated agarose gel and photographed during illumination with UV light.
HHV-8 sequence determination
Detectable PCR bands were excised from the agarose gel and ligated into a pCRII vector (Invitrogen) for sequencing. Following bacterial transformation, plasmids containing appropriately sized inserts were sequenced using the Sequenase II kit (US Biochemicals, Cleveland, OH, USA) following the manufacturer's instructions using 35 S ␣ deoxyadenosine triphosphate (Amersham, Arlington Heights, IL, USA). The KS330 233 sequences were then compared using the DNAsis program (Hitachi, San Bruno, CA, USA).
Statistical analysis
A paired Student's t-test was used to assess whether differences in viral detection reached statistical significance between groups. Comparisons between patient groups in terms of the demographic and baseline data were performed using the two-sample t-test or Wilcoxon rank sum test for continuous data and Fisher's exact test for categorical data. Progression-free and overall survival times were calculated from the date of transplant and summarized using KaplanMeier curves 20 and compared using the Cox proportional hazards model.
Results
Sample collection
One hundred and ninety patients were enrolled into the study and of these, 93 patients were randomized to have their autografts processed through the Ceprate SC device. Peripheral blood mononuclear cell samples were collected prior to mobilization chemotherapy and on the initial day of leukapheresis. In addition, aliquots of the initial leukapheresis and CD34-enriched and depleted products were collected for viral burden assessment. Sufficient DNA was available for analysis in 41 of these patients (Ͼ1.2 g of DNA in four of the five samples). When the baseline characteristics of these patients were compared to those of the entire cohort, no significant differences were noted with respect to age, sex, performance status, disease remission, ␤2-microglobulin level or type of induction chemotherapy. The time from diagnosis to study enrollment was slightly shorter for the patients studied compared to the entire 190 patient cohort (6 vs 8 months, P = 0.037).
HHV-8 identification in PBMCs before and after mobilization chemotherapy
Thirty-nine PBMC samples collected prior to mobilization chemotherapy from the 41 study patients had sufficient 155 DNA and yielded the appropriately sized PCR product after amplification with the positive control ␤-actin primers. Of these pre-mobilization PBMC samples, two samples (4.9%) produced the appropriately sized 233 bp product after PCR amplification using the KSHV330 233 primers ( Figure 1 ). In contrast, DNA was assessable in 37 PBMC samples collected on the initial day of leukapheresis and nine of these samples had detectable HHV-8 DNA (24.3%, Table 1 ). This difference was statistically significant (P = 0.016) (Figure 2 ). Of the two patients with detectable HHV-8 within PBMCs prior to mobilization chemotherapy, one also had HHV-8 identified within the post-mobilization PBMC product.
HHV-8 identification in autograft products
The KSHV330 233 sequence was found in 16 of 40 (40.0%) assessable leukapheresis products, yet in only five of the 33 (15.2%) analyzable autografts collected after CD34 enrichment (P = 0.016). The percentage of discarded CD34-depleted products with detectable HHV-8 was comparable to that found for the CD34-enriched products, five of 37 positive (13.5%). The HHV-8 detection rate was statistically significantly higher in the leukapheresis specimens than in the CD34-depleted products as well (P = 0.003) (Figure 3 ).
Concordance of HHV-8 detection in patient samples
For 11 patients, HHV-8 DNA was detectable in more than one sample collected ( Table 2) . Of the nine patients with HHV-8 detectable within the PBMCs collected on the first leukapheresis day, seven had HHV-8 DNA in the leukaph- Bone Marrow Transplantation eresis product. In contrast, when virus was not detectable in the leukapheresis product, only rarely was HHV-8 found within the PBMCs collected on the same day (n = 2 of 21).
Confirmation of HHV-8 DNA and sequencing results
In order to confirm accuracy of the results, aliquots of DNA from the leukapheresis specimen and PBMC specimen collected on the same day for patients 402, 508, 514, 2511 and 3104 were amplified again. These patients were chosen since HHV-8 was detected in both of the specimens in the initial experiment. The appropriate 233 bp product was detected again in every case except in the PBMC specimen from patient 508. The 233 bp products obtained were extracted from an agarose gel and ligated into pCRII plasmid vectors. Bacteria were transformed and three clones derived from each patient sample were sequenced bidirectionally. The six KSHV330 233 sequences obtained from a given patient were identical (except for a 1 bp difference in one of six clones from patient 514); yet there were sequence differences between patients. In fact, when these sequences were compared to the original KSHV330 233 sequence reported by Chang et al 10 (GenBank No. U75698) as many as seven nucleotide differences were noted ( Figure  4) . Interestingly, the sequences found in these myeloma patients were more comparable to that found within the BC-2 cell line which was derived from a patient with a pleural effusion lymphoma. 19 To provide additional confirmation of the PCR results, DNA from eight additional samples were amplified using primers specific for a second region of HHV-8, ORFK9. This part of the viral genome encodes for a potential oncogene, viral interferon regulatory factor (vIRF). All five of the samples positive using the KSHV330 233 primers were also positive with the primers for ORFK9 ( Figure 5 ). However, one of the remaining three samples which was negative using the KSHV330 233 primers now had detectable viral ORFK9 DNA. This latter finding may be due to the increased sensitivity we have noted with these vIRF primers.
Patient outcome
No differences in progression-free survival or overall survival were noted between the groups of patients studied vs the entire 190 patient cohort. In addition, the presence of HHV-8 within the autograft did not impact overall or progression-free survival.
Discussion
Recently, we demonstrated that bone marrow stromal cell cultures derived from patients with multiple myeloma are commonly infected with HHV-8 DNA. 15 Stromal cell cultures from normal patients and patients with other hematological malignancies were not infected. Furthermore, using reverse transcriptase-PCR (RT-PCR), viral RNA transcripts of the homologues to IL-6 (vIL-6), macrophage inhibitory protein-1␣ (vMIP-1␣), IL8-R (vIL8-R) and interferon regulatory factor (vIRF) have been isolated in the myeloma stro- 
Open spaces represent samples that were either unavailable or had inadequate DNA for analysis. 
Figure 3
The proportion of autografts with HHV-8 detectable using PCR and the KSHV330 233 primers. CD34 + and CD34 − represent the CD34-enriched and -depleted products, respectively. P values are based upon comparisons with the leukapheresis product. mal cell cultures. 21 Although these findings could theoretically be explained by an artifact of cell culturing, virus was also identified using in situ hybridization and PCR on fresh bone marrow core biopsies from myeloma patients. 22 Eighteen of 21 biopsies derived from these patients had positive staining with an HHV-8 ORF72 probe while biopsies derived from leukemia, lymphoma and normal patients were negative for HHV-8 (n = 27). Interestingly, the three myeloma bone marrow biopsies which were viral negative were from patients in clinical remission following either conventional or high-dose chemotherapy.
The stromal cells infected with the virus were characterized and found to be dendritic in origin based upon their co-expression of CD68, CD83 and fascin. [23] [24] [25] Recent studies have demonstrated the importance of this cell type in the induction of B cell maturation and growth. 26 The existence of HHV-8 and subsequent expression of viral proteins which could stimulate plasma cell growth may provide a mechanism which could ultimately lead to malignant development and/or support the growth of previously transformed myeloma cells. It is interesting to note that HHV-8 has been found within the bone marrow stromal cultures of ෂ 25% of the patients with monoclonal gammopathy of undetermined significance (MGUS) studied to date, implying that HHV-8 infection may precede malignant transformation. 15 Whether the patients with MGUS and detectable HHV-8 genome within their bone marrow represent the cohort of patients who will ultimately develop multiple myeloma remains to be seen. Current studies are in progress to answer this important question.
HHV-8 has only rarely been detectable within the unenriched peripheral blood mononuclear cells from our myeloma patients using this assay. Since bone marrow-based dendritic cells are large and generally adherent, they are rarely identified in the circulation. Nevertheless, following enrichment for PBMCs expressing markers present on the BM dendritic cells infected with virus, CD68 and CD83, using immunomagnetic bead purification, HHV-8 genome was detected in 29 of 36 peripheral blood specimens from myeloma patients at various stages of their disease. 16 In contrast, only one of 17 specimens collected from patients with other malignancies or from normal donors had evidence of HHV-8. These results suggest that the majority of myeloma patients have circulating HHV-8 infected dendritic cells but that these cells are rare and frequently below the threshold level of sensitivity using the current assay on unenriched PBMC DNA.
The present study confirms our previous finding that HHV-8 can be detected in patients with multiple myeloma and also implies that our current method of mobilizing stem cells with cyclophosphamide, prednisone and G-CSF can also mobilize these infected cells. In addition, 40% of the unmanipulated leukapheresis products collected from these patients had detectable HHV-8. It is likely that an even greater percentage of autografts are virally infected since DNA from only 100 000 cells was used in the PCR amplification procedure. Since the final unmanipulated autograft contained a median 8 × 10 8 cells/kg per patient in this study, only a small percentage of the stem cell product (Ͻ0.01%) was assessed for viral DNA.
Because the CD34 antigen is not expressed on the virally infected dendritic cells in MM bone marrow stromal cell cultures, it is not surprising that CD34 enrichment of autografts also reduces the percentage of autografts with detectable HHV-8 as demonstrated in this report. The percentage of autografts that had detectable HHV-8 fell from 40% to 12% following CD34 enrichment using the Ceprate SC device. This change is modest but would be anticipated given the method of viral DNA ascertainment and autograft processing. Our PCR assay, in effect, measures whether the sample contains HHV-8 infected cells at a frequency greater than assay sensitivity. These HHV-8 infected cells will be contained in the CD34-negative fraction of the autograft given the lack of CD34 expression by these dendritic cells. Following CD34 enrichment, CD34 cell purity increased from 0.9% to 67% in this cohort of patients. Consequently, the undesirable CD34-negative cell fraction decreased from 99.1% to 33%, which is only a 0.5 log change in purity. Therefore, only those leukapheresis products with HHV-8 contamination within 0.5 log of our threshold ability to detect virus would be anticipated to have a subsequent CD34-enriched product with no detectable HHV-8.
In this clinical trial, autografts were also assessed for myeloma tumor burden before and after CD34 enrichment. We found that the percentage of autografts with detectable myeloma cells fell from 86% to 46% following CD34 enrichment. 27 This 0.3 log reduction in tumor cell detection rate is similar but slightly less than the 0.5 log reduction in viral detection rate noted in this study. This latter finding may be explained by a preferential elimination of the HHV-8 infected dendritic cells from the autograft product during processing. Since the CD34-depleted products also were less likely to contain detectable virus, the virally infected dendritic cells may be preferentially retained by the immunoadsorption column. Because these dendritic cells are adherent to plastic in our long-term stromal cell cultures, these cells may also adhere to the plastic or other inert products within the separation device. We found that, overall, the CD34 selection procedure reduced myeloma cell tumor burden within the autografts by a median of 3.2 logs. 27 This beneficial effect was primarily due to a reduction in autograft cell number following CD34 enrichment. Given these findings, one would anticipate a similar or even greater efficiency of autograft viral load reduction by this purging procedure. It also may explain why dendritic cells derived from a purified CD34 cell fraction were not found to be contaminated by HHV-8 by another group. 28 Despite our own group's findings and confirmatory results by others, 29, 30 many investigators have failed to detect HHV-8 within multiple myeloma bone marrow and dendritic cell cultures. [31] [32] [33] [34] [35] In fact, a recent paper by the group in Heidelberg failed to find any evidence of HHV-8 in the similarly obtained leukapheresis products of multiple myeloma patients following G-CSF mobilization. 36 While our results have been suggested to represent an artifact or PCR contamination, [37] [38] [39] this conclusion seems unlikely. Positive samples sequenced from five separate patients revealed that the amplified band was the anticipated KS330 233 product. Furthermore, these KS330 233 sequences were unique for each patient and did not match the gene sequence of the positive control used (derived from the KS-1 cell line). 40 Finally, amplification of a second region of HHV-8 confirmed the existence of virus in each sample tested. Instead, the conflicting results may be explained by variations in the ORF26 sequence between that originally described in Kaposi's sarcoma tissue, and that found in the multiple myeloma (MM) patients.
It is of interest that the majority of studies failing to detect HHV-8 DNA in MM have used a nested PCR technique to search for viral ORF26. The ORF26 sequence which contains the KS330 233 sequence is known to vary substantially between HHV-8 isolates. This has led to the classification of HHV-8 subtypes based upon shared nucleotide variations. 41 The MM-derived sequences identified in this report appear restricted and most closely match that found in the BC-2 cell line. 42 This particular HHV-8 subtype (C3) has the greatest base pair variability within the ORF26 coding region (1.5%). 41 Since the use of nested PCR relies on sequence homology to four separate oligonucleotide primers, the lack of amplified product may be due to mismatches between these primers (designed to match the original HHV-8 subtype A sequence 10 ) and the HHV-8 genome present in MM tissues. This wavering PCR sensitivity was recently reported by the group at Loyola which used multiple sets of ORF26 primer pairs. 43 Nucleotide differences in HHV-8 subtypes may also explain the results reported by Tisdale and colleagues. 44 These investigators found a high prevalence of HHV-8 sequences in MM bone marrow stromal material using primers to ORF26 yet failed to obtain PCR products when other HHV-8 regions were assayed.
In conclusion, this work demonstrates that mobilized peripheral blood and autografts derived from patients with multiple myeloma are frequently contaminated with HHV-8. Autograft CD34 enrichment can reduce autograft viral burden, yet the importance of this benefit remains unanswered. Hopefully, as more is learned about the relationship between HHV-8 infection and multiple myeloma pathogenesis, the clinical relevance of these findings will become more apparent.
